Multicenter phase II study of capecitabine plus cisplatin as first-line therapy for human epidermal growth factor receptor 2-negative advanced gastric cancer: Yokohama Clinical Oncology Group Study YCOG1107

ConclusionXP as first-line therapy is effective and well tolerated by patients with HER2-negative AGC.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research